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Abstract
Growth arrest-specific protein 6 (gas6) activities are mediated through the Tyro3, Axl, and Mer family of receptor tyrosine
kinases. Gas6 is expressed and secreted by a wide variety of cell types, including cells of the central nervous system (CNS). In
this study, we tested the hypothesis that administration of recombinant human Gas6 (rhGas6) protein into the CNS
improves recovery following cuprizone withdrawal. After a 4-week cuprizone diet, cuprizone was removed and PBS or
rhGas6 (400 ng/ml, 4 mg/ml and 40 mg/ml) was delivered by osmotic mini-pump into the corpus callosum of C57Bl6 mice
for 14 days. Nine of 11 (82%) PBS-treated mice had abundant lipid-associated debris in the corpus callosum by Oil-Red-O
staining while only 4 of 19 (21%) mice treated with rhGas6 had low Oil-Red-O positive droplets. In rhGas6-treated mice,
SMI32-positive axonal spheroids and APP-positive deposits were reduced in number relative to PBS-treated mice. Compared
to PBS, rhGas6 enhanced remyelination as revealed by MBP immunostaining and electron microscopy. The rhGas6-treated
mice had more oligodendrocytes expressing Olig1 in the cytoplasm, indicative of oligodendrocyte progenitor cell
maturation. Relative to PBS-treated mice, rhGas6-treated mice had fewer activated microglia in the corpus callosum by Iba1
immunostaining. The data show that rhGas6 treatment resulted in more efficient repair following cuprizone-induced injury.
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Introduction
Gas6, the product of growth arrest-specific gene 6 (Gas6), is
upregulated during growth arrest [1–3], and is expressed and
secreted by a wide variety of cell types including neurons [3,4].
Gas6 is a vitamin K-dependent growth factor and is the ligand for
the Tyro3, Axl, and Mer (TAM) receptor tyrosine kinase family
[5,6]. In a concentration-dependent manner, Gas6 induces
signaling through TAM receptors and exerts its biological effects
[7–12]. Gas6 signaling induces cell survival [13,14], proliferation
[15,16], phagocytosis [17], differentiation [18], and prevents cell
apoptosis [19,20]. Gas6 binds phosphatidylserine and promotes
phagocytosis of apoptotic cells [21]. Shed soluble forms of Axl and
Mer bind Gas6 and can function as decoy receptors regulating
Gas6 bioactivity [22,23]. In multiple sclerosis (MS) lesions, up-
regulation of soluble Axl and Mer negatively correlates with Gas6
expression, suggesting that the dysregulation of protective Gas6
receptor signaling may prolong lesion activity [24].
Several studies in vitro and in vivo indicate that an interaction
between Gas6 and its receptors has physiologic relevance [4,5].
Our previous studies in vitro demonstrated that Gas6 protected
human and wild type (WT) rodent oligodendrocytes against insulin
withdrawal and TNF-alpha induced cytotoxicity [19]. This
protection was lost in cultured oligodendrocytes isolated from
Axl knock-out mice, but not from WT or Tyro3 knock-outs. A
protective effect was mediated by Akt activation and the effect was
blocked by treatment with a PI3 kinase inhibitor suggesting that
Gas6/Axl/PI3 kinase/AKT signaling may be important for
maintaining oligodendrocyte survival under conditions of stress.
In another study, we showed that Axl knock-out mice had delayed
recovery and prolonged axonal damage following cuprizone
toxicity, supporting the observation that the Axl receptor was
important for recovery [25]. Also, Gas6 knock-out mice had fewer
mature oligodendrocytes and greater microglial activation follow-
ing cuprizone toxicity and recovery, indicating that TAM receptor
activation and regulation affected multiple CNS cell types [26].
Cuprizone administration into mouse chow induces oligoden-
drocyte cell death, demyelination, axonal injury and microglial
activation in the corpus callosum 3–4 weeks following adminis-
tration. Upregulation of cytokines and chemokines occurs, along
with gliosis, peaking at 4 weeks of cuprizone treatment [27–32]. In
this study, we tested the hypothesis that direct administration of
rhGas6 into the corpus callosum by osmotic mini-pump improves
recovery following cuprizone toxicity.
Materials and Methods
Animals and cuprizone treatment
C57Bl6J mice were housed in a temperature and humidity-
controlled environment with a 12-hr light-dark cycle. Mice were
maintained on standard mouse chow and given water ad libitum
prior to cuprizone treatment. Male 8-week-old mice were fed
0.2% (w/w) cuprizone (bis-cyclohexanone oxalydihydrazone,
Sigma; St. Louis, MO) in powdered chow ad libitum for 4 weeks.
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e15748Food containing cuprizone was changed every 2 days for 4 weeks.
Immediately after cuprizone withdrawal from the diet, rhGas6 or
PBS mini-pump treatment was initiated for an additional 14 days.
RhGas6 or PBS administration
The Alzet Brain Infusion Kit 3 (Alzet Corp., CA) and the Alzet
osmotic mini-pump (Alzet 1002, Alzet Corp., CA), were used to
deliver rhGas6 or PBS (vehicle) directly into the corpus callosum.
Sterile rhGas6 diluted in PBS was kindly provided by Amgen
(Thousand Oaks, CA). The assembly and pre-incubation of the
mini-pump were performed according to the manufacturer’s
instructions. Briefly, one day before surgery, mini-pumps were
connected to the brain infusion cannula by catheter tubing and
filled with either rhGas6 or PBS. The filled infusion assembly with
attached osmotic mini-pump was incubated overnight in sterile
saline at 37uC.
RhGas6 was diluted in PBS and three doses, 400 ng/ml
(5.2 nM); 4 mg/ml and 40 mg/ml, were administered by mini-
pump. PBS was infused as a control. For treatment, mice were
anesthetized with a mixture of Ketamine (30mg/kg)/Xylazine
(6 mg/kg)/Acepromazine (1 mg/kg), and placed in a stereotaxic
frame with non-traumatic ear-bars to hold the skull in place. A
23G needle was used to create a hole above the entry site for the
sterile stainless steel mini-pump cannula and the stereotactic arm
holding the cannula was lowered into place unilaterally targeting
the corpus callosum. The coordinates of the hole for the cannula
were 1.0 mm anterior to the bregma, 0.8 mm lateral, and 2.3 mm
ventral to the skull surface. The cannula was implanted and glued
to the skull surface using veterinary skin adhesive (Loctite 454,
Global Test Supply, NC). Thereafter, the cannula was covered by
orthodontic powder diluted in acrylic resin liquid (Lang Dental
Inc., IL). The mini-pump was inserted beneath the skin at the right
scapula and the skin was closed using surgical adhesive. The
volume and the rate of delivery of PBS or rhGas6 by mini-pump
were 250 nanoliters per hour continuously for 14 days. Mice were
housed individually to avoid possible damage to the mini-pump.
All protocols were approved by the Animal Care and Use
Committee at the Albert Einstein College of Medicine. The
Animal Use Protocol Number is 20080308.
Tissue preparation, immunohistochemistry and
Oil-Red-O staining
After 2 weeks of rhGas6 or PBS treatment, mice were
euthanized by cardiac perfusion with 4% paraformaldehyde
(PFA). The brains were fixed in 4% PFA for 24 h, cryoprotected
in 30% sucrose, and 20 mm frozen sections were prepared and
used for analysis from the area corresponding to sections 230–250
of Sidman’s Atlas of the mouse brain and spinal cord [33]. To
confirm that a significant reduction in myelin occurred in the
corpus callosum of mice on the cuprizone diet at 4 weeks, and to
examine the extent of remyelination at 14 days following
cuprizone withdrawal and rhGas6 or PBS treatment, multiple
non-serial coronal sections of mouse brain were stained with
myelin basic protein (MBP) monoclonal antibody, SMI99. For
immunohistochemistry, all sections were incubated for 30 min
with 16Tris-buffered saline pH 7.4 (16TBS), containing 0.25%
Triton X-100 and 3% H2O2, followed by a 1 h incubation in 5%
goat serum and 5% nonfat dry milk in 16TBS. Antibodies were
diluted in 5% nonfat dry milk in 16 TBS and sections were
incubated overnight at 4uC. Following incubation, the sections
were washed 3 times in 16 TBS containing 0.1% Triton X-100
and incubated with biotinylated secondary antibody, as detailed in
the Vectastain Avidin–Biotin complex kit (Vector Laboratories,
Burlingame, CA), and were visualized by 3939-diaminobenzidine
(DAB, Sigma). The MBP-positive immunostaining was evaluated
by Gray value using ImageJ software, with images photographed
at a magnification of 6400. This method quantified the extent of
MBP expression. Multiple non-serial sections per mouse were
used. Data were expressed as mean 6 SD.
SMI32, APP, Iba1 and Olig1 immunostaining was performed as
described above for MBP. SMI32 and APP are markers of axonal
damage [34-36]. SMI32-positive axonal swellings and APP-positive
deposits were visualized and counted at a magnification of6400 in
the middle and lateral regions of the corpus callosum at the fornix.
Three to six non-serial sections per mouse were used and more than
3 mice per group were examined. Data were expressed as mean 6
SD. APP positive deposits were counted and expressed as mean 6
SD for multiple non-serial sections per mouse and four mice per
group. Iba1 was used as a microglial cell marker [37]. Olig1 was
used as a marker of oligodendrocyte progenitor maturation.
Cytoplasmic Olig1-positive immunostaining was used as a marker
of mature oligodendrocytes [38].Iba1- and Olig1-positivecells were
visualized and counted as above. The number of Iba1- and Olig1-
positive cells was expressed as mean 6 SD for four mice per group.
The lysochrome dye, Oil-Red-O, was used to demonstrate
triglycerides and cholesterol esters which associate in particular
with lipid deposits in cells and tissues after injury [39]. Frozen
sections were incubated in distilled water for 1 min, followed by a
2 min incubation in 100% propylene glycol (Polyscientific; Bay
Shore, New York), and transferred to Oil-Red-O (0.5% solution in
propylene glycol, Polyscientific; Bay Shore, New York), for 36 h at
room temperature. Sections were incubated for 1 min in 85%
propylene glycol, lightly stained with hematoxylin and mounted
with glycerine jelly mounting medium (Polyscientific; Bay Shore,
New York). Oil-Red-O positive deposits were visualized by light
microscopy. Multiple, non-adjacent sections per mouse within
regions 230–250 of the corpus callosum were evaluated [33].
Once the positive effect of 400 ng/ml and 4 mg/ml of rhGas6
were revealed following Oil-Red-O staining, SMI32 and MBP
immunostaining, we focused the remainder of our analysis on the
two lower rhGas6 doses. All comparative analyses of MBP, Olig1
and Iba1 immunostaining and for EM focused on the corpus
callosum at the midline [40]. Four mice per group were evaluated
for APP, Iba1 and Olig1 immunostaining.
Electron Microscopy (EM)
Following cardiac perfusion with 4% PFA, brain samples were
fixed with 2.0% PFA, 2.5% glutaraldehyde and 0.1 M cacodylate
buffer (pH 7.4), and postfixed with 1% osmium tetroxide followed
by1%uranylacetate,dehydratedthroughagradedseriesofethanol
and embedded in LX112 resin (LADD Research Industries,
Burlington VT). Ultrathin (80 nm) sections were cut on a Reichert
Ultracut UCT, stained with 0.01% uranyl acetate followed by lead
citrate and viewed in a JEOL 1200EX or an Hitachi HS600. Brain
sections within regions 230–250 were taken and oriented such that
cross sections of axons within the corpus callosum were obtained.
Non-serial sections were evaluated from each mouse (3 mice per
group) and at least four fields per mouse were taken at a
magnification of 65000. Image J software was used to calculate
axonal diameter, myelin thickness and g-ratios. Non-serial sections
were evaluated and 100 axons per mouse were counted. The g-ratio
represents the ratio of the diameter of the axon to the diameter of
the axon plus myelin. Approximately 14 fields (per animal) with
dystrophic axons and axonal spheroids were taken randomly at
65000 and their sizes were measured in both PBS- and rhGas6-
treated mice. All data were reported as the mean 6 SD.
Antibodies. Both SMI99 (MBP, 1:1500) and SMI32 (1:1000)
were purchased from Covance Inc, Emeryville, CA. Mouse anti-
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was purchased from Millipore Corp., CA. Iba1 antibody for
immunohistochemistry (1:400) was purchased from WAKO,
Richmond, VA. Olig1 antibody (DF389, 1:1000) was kindly
provided by Dr. John Alberta from Dana-Farber Cancer Institute,
Boston, MA.
Statistical analysis
The Kruskal-Wallis statistical analysis was applied (Systat 7.0).
P,0.05 was considered significant.
Results
rhGas6 reduces Oil-Red-O positive deposits
post-cuprizone treatment and withdrawal
Following treatment with three doses of rhGas6 for 14 days, the
corpus callosum of 15 of 19 mice (79%) was completely negative
for Oil-Red-O (Fig. 1G-L). Only 4 of 19 mice (21%) treated with
400 ng/ml and 4 mg/ml of rhGas6 had low or moderate staining.
By contrast, following PBS treatment, only 2 of 9 mice (18%) were
Oil-Red-O negative, whereas 9 of 11 mice (82%) were strongly
positive (Fig. 1A–F). Mice fed powdered chow and receiving PBS
were Oil-Red-O negative while mice treated with cuprizone for
four weeks had extensive positive staining within the corpus
callosum (data not shown). These results demonstrated that all
rhGas6 doses had a beneficial effect on the clearance of cellular
and myelin debris following cuprizone toxicity.
RhGas6 reduces SMI32+ and APP+ axonal swellings
Brain sections from both PBS- and rhGas6-treated mice were
evaluated for evidence of axonal damage using the monoclonal
antibody SMI32 that recognizes a non-phosphoepitope on NF
proteins H and M, and an APP monoclonal antibody which detects
accumulation of APP due to failed axonal transport. The number of
positive axonal swellings was counted as a marker of axonal
damage. Representative examples are shown of SMI32 positive
axonal swellings in PBS-treated mice (Fig. 2A and E), and in
rhGas6-treated mice at the various doses (Fig. 2B–D and F–H). The
number of axonal swellings in PBS-treated mice was 27.468.8
(n=11). In mice treated with rhGas6 the number of axonal
swellings was 14.9611.3 (400 ng/ml, p,0.02, n=7), 10.7612.1
(4 mg/ml, p,0.01, n=9), and 14.363.7 (40 mg/ml, p,0.05, n=3).
Also, APP immunoreactivity was significantly reduced in rhGas6-
treated mice relative to PBS-treated mice (Fig. 2I–K). In PBS-
Figure 1. Treatment with rhGas6 reduces Oil-Red-O positive deposits after cuprizone intoxication. A–F, corpus callosum of mouse brain
after PBS treatment. Extensive deposition of Oil-Red- O positive droplets can be seen (arrows). Brain sections from mice treated with 400 ng/ml (G
and J), 4 mg/ml (H and K), and 40 mg/ml (I and L) of rhGas6 demonstrate a beneficial effect for all tested rhGas6 doses. Arrows indicate the clearance
of debris from the corpus callosum. Low and high magnification, 650 and 6400.
doi:10.1371/journal.pone.0015748.g001
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while in rhGas6-treated mice it was 7.062.9 (400 ng/ml, p,0.05,
n=4) and 7.563.7 (4 mg/ml, p,0.05, n=4). Thus, these results
showed that all tested doses of rhGas6 significantly reduced the
number of axonal swellings relative to the PBS-treated group.
RhGas6 enhances remyelination after cuprizone toxicity
MBP immunoreactivity was used to estimate the extent of
demyelination in the corpus callosum following cuprizone
intoxication and to evaluate remyelination after cuprizone
withdrawal in the PBS- and rhGas6-treated groups. At 4 weeks
post treatment with cuprizone, there was visible demyelination
relative to the untreated mice maintained on powdered chow
(Fig. 3A–C). The gray value analysis of the intensity of MBP
expression confirmed demyelination 4 weeks after cuprizone
treatment: 164.461.3 (untreated mice, n=2) vs. 127.4610.7
(cuprizone-treated mice, n=3). At 14 days after cuprizone
removal and treatment with either PBS or rhGas6, remyelination
was observed (Fig. 3D–G). The gray value of PBS-treated mice
was 135.566.0 versus 140.366.6 (400 ng/ml rhGas6, NS, n=7),
144.967.6 (4 mg/ml rhGas6, n=9, p,0.02) and 142.261.9
(40 mg/ml rhGas6, p,0.05, n=3). Thus, based on gray values,
we established that the extent of remyelination was higher in all
rhGas6-treated mice versus PBS-treated mice; however, only the
4 mg/ml and 40 mg/ml groups were statistically significant.
RhGas6 accelerates maturation of oligodendrocyte
progenitor cells
Oligodendrocyte progenitor development can be used as a
marker of repair after damage caused by cuprizone toxicity. Olig1
is critical for the maturation of oligodendrocyte progenitor cells
(OPC), and Olig1 immunostaining becomes progressively more
cytoplasmic during OPC maturation. Thus, we used Olig1
cytoplasmic immunostaining as a maturation marker during
regeneration. In rhGas6-treated mice, the values were
25.0618.2 (400 ng/ml, NS, n=4) and 39.067.1 (4 mg/ml,
p,0.05, n=4) while in PBS-treated mice it was 12.065.35,
n=4 (Fig. 4). Also, the percentage of cells with Olig1 positive
cytoplasmic localization relative to the total number of Olig1
positive cells was increased in rhGas6-treated mice. In PBS-treated
mice, the mean percentage was 72.8% 67.4. The mean
percentage was 89.2% 63.7 in 400 ng/ml rhGas6-treated mice
and 96.6% 61.8 in 4 mg/ml rhGas6-treated mice. Therefore,
these findings showed that the number of cells with Olig1-positive
cytoplasmic localization was increased in rhGas6- treated mice.
Number of myelinated axons is increased in mice treated
with rhGas6
EM was performed to determine whether the increased MBP
immunoreactivity and enhanced maturation of oligodendrocytes
in the rhGas6-treated groups of mice reflected more myelinated
axons in the corpus callosum. More structured tissue architecture,
organized axons as well as more myelinated axons in rhGas6-
treated mice relative to PBS-treated mice were observed (Fig. 5).
While administration of 400 ng/ml rhGas6 increased the number
of myelinated axons (Fig.5B), it was not statistically significant
relative to PBS treatment (Table 1). The number of myelinated
axons was significantly increased (p,0.02) in mice treated with
4 mg/ml rhGas6 (Fig. 5C). Axonal diameter was smaller in mice
treated with rhGas6- versus PBS-treated mice, whereas only 4 mg/
ml rhGas6 was statistically significant. The g-ratio was significantly
decreased in rhGas6- versus PBS-treated mice, indicating
Figure 2. Treatment with rhGas6 improves axonal integrity after cuprizone challenge. SMI32 and APP immunostaining of corpus callosum
sections from mice treated for 14 days with PBS (A and E), 400 ng/ml (B and F), 4 mg/ml (C and G), 40 mg/ml of rhGas6 (D and H). Magnification650
(A–D), and6400 (E–K). Increased number of SMI32- positive axonal swellings is observed in the PBS-treated mice (A–E) versus three doses of rhGas6-
treated mice (B–H). Arrows show several axonal swellings indicating breakdown in axonal structure. I–K demonstrate APP immunostaining in mice
treated with PBS (I), 400 ng/ml (J) and 4 mg/ml of rhGas6 (K). Arrows show APP positive deposits in the corpus callosum, 6400.
doi:10.1371/journal.pone.0015748.g002
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showed that relative to PBS treatment, administration of rhGas6
enhanced remyelination in the corpus callosum 14 days following
treatment.
To determine whether axonal swellings detected by SMI32
immunostaining constituted dystrophic axons or spheroids (10–
50 mm), we measured the size of axonal swellings in mice treated
with PBS and rhGas6. Dystrophic axons ranged from 3.0 mmt o
9.5 mm in diameter while axonal spheroids were greater than
10.0 mm in diameter (Fig. 6). The percentage of axonal spheroids
and dystrophic axons was calculated from the total number of
injured axons from approximately 14 randomly selected fields at a
magnification65000. The percentage of smaller dystrophic axons
was higher in rhGas6- versus PBS-treated mice: 77% (400 ng/ml
rhGas6); 86% (4 mg/ml rhGas6) compared to 42% (PBS). By
contrast, the percentage of axonal spheroids was greater in PBS-
treated relative to rhGas6-treated mice: 23% (400 ng/ml rhGas6);
14% (4 mg/ml rhGas6) compared to 58% (PBS). In addition, EM
revealed more myelin and lipid debris in PBS-treated relative to
rhGas6-treated mice. Representative micrograph (Fig. 6A) shows
myelin debris and lipid deposits in PBS-treated mouse. Therefore,
EM supported our observation that rhGas6 administration had a
positive effect on the clearance of debris.
Number of activated microglial cells not significantly
altered after PBS or rhGas6 treatment
We used Iba1 as a marker of microglial cell activation to
determine whether following direct delivery of rhGas6 versus PBS,
there was a reduction in Iba1-positive immunoreactivity. Repre-
sentative Iba1-positive microglia immediately following cuprizone
treatment for 4 weeks is shown (Fig. 7). Abundant Iba1-positive
microglia (92.064.2, n=4) was seen immediately following 4
weeks of cuprizone treatment. Significant reduction in Iba1-
positive microglial cells at 14 days following cuprizone withdrawal
Figure 3. MBP immunostaining shows that rhGas6 treatment enhances remyelination following cuprizone toxicity. Relative to
untreated mice (A) there is demyelination of the corpus callosum of mice fed cuprizone for 4 weeks (B and C). A comparison of remyelination
assessed by MBP staining of the PBS treated mice (D) versus rhGas6 treatment for 14 days following cuprizone withdrawal (E – 400 ng/ml; F - 4 mg/ml;
G–4 0mg/ml of rhGas6) shows that the extent of remyelination is greater in rhGas6-treated mice, 6400.
doi:10.1371/journal.pone.0015748.g003
Figure 4. Number of Olig1-positive mature oligodendrocytes is increased in rhGas6-treated mice. Olig1-positive nuclear and
cytoplasmic localization in cells (A–C). Increased numbers of cells with Olig1-positive cytoplasmic localization (arrows) in mice treated with 400 ng/ml
(B), and 4 mg/ml rhGas6 (C) versus PBS-treated mice (A), are shown, 6400.
doi:10.1371/journal.pone.0015748.g004
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number of Iba1-positive cells in the rhGas6-treated mice was
38.0614.6, 400 ng/ml, (n=4), and 34.063.7, 4 mg/ml, (n=4)
relative to PBS-treated mice 48.0617.7, (n=4), the differences
were not statistically significant.
Overall, these results suggest that compared to PBS, rhGas6
treatment resulted in more efficient repair of the corpus callosum
following cuprizone toxicity. This conclusion is based upon
enhanced clearance of cellular and myelin debris and remyelina-
tion, increased axonal survival and integrity as well as OPC
maturation.
Discussion
Gas6 is a survival factor for neurons and glial cells involved in
myelination as well as a growth and anti-apoptotic factor for
Schwann cells [41]. Gas6 and the TAM receptors are widely
expressed in the rodent nervous system [4]. In this study, we show
that compared to mice receiving PBS, rhGas6 administration
directly to the corpus callosum by osmotic mini-pump for 14 days
enhanced the clearance of lipid-laden debris, remyelination and
reduced axonal damage that resulted from 4 weeks of ingestion of
cuprizone in powdered chow. Indeed, 14 days after treatment, nine
ofelevenPBS-treatedmicehadextensivelipid-associateddropletsin
the corpus callosum and only four of nineteen mice treated with
multiple rhGas6 doses had low or moderate Oil-Red-O positive
staining. These data demonstrated that in vivo, rhGas6 enhanced the
clearance of myelin debris which was efficiently eliminated after
cuprizone damage. In another study, in which lysolecithin was
injected directly into the cervical spinal cord, large deposits of Oil-
Red-O were observed, correlating with areas of demyelination 7–14
days after injection. Despite the observation that the density of the
lipid-laden droplets inside the lesion area decreased over the time
course examined, it did not disappear entirely [42]. Perhaps,
rhGas6 can be considered as a potential enhancer of debris
clearance and remyelination following spinal cord injury.
Although the number of activated microglia in PBS- relative to
rhGas6-treated mice was not significantly different, rhGas6 likely
was more effective for clearance of debris. A positive effect of Gas6
on dying cell clearance in vitro has been reported for multiple cell
types [43–46], and the ability of rhGas6 to affect phagocytosis in
murine microglia by acting on Axl/Mer has been shown
previously in vitro [47].
The clearance of cellular and myelin debris might be an initial
and important early step for recovery in the corpus callosum.
Efficient clearance of damaged cells and myelin debris likely
impacts upon remyelination and cell survival. In this study, a
significantly greater number of SMI32-positive axonal spheroids
were observed in PBS- versus rhGas6-treated mice. After
treatment with different doses of rhGas6, all doses noticeably
reduced the number of SMI32 positive axonal swellings relative to
PBS treatment. SMI32-positive immunoreactivity in axons as well
as the presence of axonal swellings or spheroids is considered
pathologic and was previously shown to occur during cuprizone
treatment and during MOG-induced experimental autoimmune
encephalomyelitis [34,35,48,49].
Increased SMI32-positive immunoreactivity correlates with
axonal injury due to dephosphorylation of neurofilament H
[25,50]. Further, SMI32 immunoreactivity is found in chronic
lesions from patients with MS [51]. Similarly, increased APP
immunoreactivity within axons represents a defect in axonal
transport and serves as a marker of axonal injury resulting from
cytoskeletal breakdown and calcium influx that interrupts
axoplasmic flow and subsequent accumulation of organelles [36].
By EM, we showed that the percentage of small dystrophic axons
Figure 5. EM shows more myelinated axons in rhGas6-treated mice. Relative to PBS (A), the number of myelinated axons was significantly
increased in mice treated with 400 ng/ml (B) and 4 mg/ml (C) rhGas6. Black arrows denote myelinated axons; white arrows show demyelinated, naked
axons, 65000.
doi:10.1371/journal.pone.0015748.g005
Table 1. Increased number of myelinated axons is observed
in mice treated with rhGas6.
Parameters PBS
rhGas6
400 ng/ml
rhGas6
4 mg/ml
Number of myelinated
axons, mean 6 SD
a
48.0620.1 80.666.6 100.5618.6**
* g-ratio, mean 6 SD
a, b 0.87760.004 0.85360.007** 0.83660.01**
Axonal diameter,
mean 6 SD
b
0.86860.063 0.75260.057 0.7060.067**
a- data was collected from four photomicrographs, 65000; 3 mice/group.
b- 100 randomly selected axons were measured per mouse.
*- g-ratio of cuprizone untreated mice was 0.80260.01 (mean 6sS D ) .
**- P,0.05.
doi:10.1371/journal.pone.0015748.t001
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large axonal spheroids was higher in PBS-treated mice relative to
rhGas6. Thus, data from EM support our conclusion that mice
treated with rhGas6 have a reduction in axonal spheroids. The
results obtained demonstrate a beneficial effect of rhGas6 on
axonal survival and the maintenance of axon integrity following
cuprizone toxicity. In this context, we previously showed in vitro
that 400 ng/ml (5.2 nM) rhGas6 had a maximal positive effect on
human oligodendrocyte survival using oligodendrocytes isolated
from human fetal spinal cord. This suggests that rhGas6 serves as a
survival factor for oligodendrocytes during development [52].
In the present study, we evaluated how rhGas6 affected
remyelination following cuprizone withdrawal by MBP immuno-
staining. We used gray value analysis to distinguish the intensity of
MBP expression between PBS- and rhGas6-treated mice.
Extensive demyelination in the corpus callosum (Fig. 3B and C),
was observed after 4 weeks of cuprizone treatment. The extensive
myelin loss had the lowest gray value which correlated with weak
MBP immunoreactivity. Our data are consistent with other studies
demonstrating demyelination in the corpus callosum 3–4 weeks
after cuprizone treatment [53,54]. Quantification of MBP staining
revealed that gray values gradually increased after cuprizone
Figure 6. EM demonstrates dystrophic axons and axonal spheroids in PBS- and rhGas6-treated mice. A. Axonal spheroids (.10 mm) are
shown in PBS-treated mice (black arrow). Myelin debris (arrowhead) and lipid droplets (white arrow), are also noted. B – 400 ng/ml, C – 4 mg/ml of
rhGas6 demonstrate dystrophic axons ranging in size from 3.0–9.5 mm in diameter (black arrow). Note microglial cell process (white arrow, B), and
astrocytes in rhGas6-treated mice (gray arrow B and C), 65000.
doi:10.1371/journal.pone.0015748.g006
Figure 7. Similar numbers of Iba1-positive microglia are present in PBS- and rhGas6-treated mice. A. Following cuprizone ingestion for 4
weeks an extensive Iba1-positive microglial activation within the corpus callosum is observed. There was significant reduction of Iba1-postive
microglia in both PBS- (B), and rhGas6-treated mice (C and D) at 14 days post treatment relative to 4 week cuprizone treated mice (p,0.02). Arrows
show Iba1-positive microglia.
doi:10.1371/journal.pone.0015748.g007
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gray values likely reflected progressive remyelination consistent
with the MBP expression. Comparative analysis of gray values in
rhGas6- versus PBS-treated mice demonstrated that 4 mg/ml and
40 mg/ml of rhGas6 were more effective for remyelination
compared to the 400 ng/ml rhGas6. Although the dose of
400 ng/ml of rhGas6 did not produce statistically significant
results, these mice also had more MBP immunoreactivity than
PBS-treated mice, indicating that enhanced clearance of debris
and reduced number of axonal spheroids was associated with
successful remyelination. EM showed increased numbers of
myelinated axons and a decreased g-ratio in rhGas6-treated mice
indicative of increased myelin thickness. Thus, the data from EM
are consistent with results obtained by MBP immunostaining. It
was shown that following acute demyelination after cuprizone
intoxication, many small caliber axons become preferentially
remyelinated [30]. We also found that the number of small
diameter myelinated axons was significantly increased in rhGas6-
treated mice. Thus, remyelination of small axons was an important
index of corpus callosum recovery.
As OPCs mature, they synthesize myelin proteins that
contribute to remyelination. We used Olig1 immunostaining as
a marker of OPC maturation to determine if direct administration
of rhGas6 affected OPC development. Olig1, a closely related
homolog to Olig2, is co-expressed with Olig2 in many cells of the
oligodendrocyte lineage. As OPCs mature, there is a shift in Olig1
immunostaining from a nuclear to a cytoplasmic localization [38].
Analysis of the corpus callosum showed that the number of cells
with Olig1-positive cytoplasmic localization was increased in
rhGas6-treated mice but only the dose of 4 mg/ml was statistically
significant. Further, the percentage of cells with Olig1-positive cells
with cytoplasmic localization relative to total number of Olig1-
positive cells was increased in mice treated with 4 mg/ml of
rhGas6.
Taken together, these data provide compelling support for
rhGas6 having a beneficial effect on corpus callosum recovery
following cuprizone toxicity. Although 400 ng/ml rhGas6 was a
therapeutic dose for the clearance of cellular debris, maintenance
of cell survival and axonal integrity, 4 mg/ml of rhGas6 was more
effective for remyelinationy. To our knowledge this is the first
report of a beneficial effect of rhGas6 administration in vivo. These
results open new avenues for rhGas6 as a treatment modality, in
addition to the study of mechanisms by which rhGas6 exerts this
effect.
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